CUSIP G2545C104 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Crescent Biopharma, Inc. (Nasdaq: CBIO) on Form 13F for 30 June 2026. Between them they reported USD 149m. The largest position belongs to Fairmount Funds Management, at USD 49m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management2 funds on PPLI.com | USD 49m | 3.3% |
| 2 | Logos Global Management1 fund on PPLI.com | USD 34m | 1.5% |
| 3 | Balyasny Asset Management25 funds on PPLI.com | USD 30m | 0.0% |
| 4 | Millennium Management6 funds on PPLI.com | USD 7.3m | 0.0% |
| 5 | RTW Investments2 funds on PPLI.com | USD 6.7m | 0.1% |
| 6 | POINT72 Asset Management17 funds on PPLI.com | USD 5.4m | 0.0% |
| 7 | Marshall Wace LLP84 funds on PPLI.com | USD 3.9m | 0.0% |
| 8 | Perceptive Advisors6 funds on PPLI.com | USD 3.7m | 0.1% |
| 9 | Two Sigma Investments35 funds on PPLI.com | USD 3.4m | 0.0% |
| 10 | Exome Asset Management2 funds on PPLI.com | USD 2.3m | 1.4% |
| 11 | Burkehill Global Management5 funds on PPLI.com | USD 1.3m | 0.0% |
| 12 | Moore Capital Management7 funds on PPLI.com | USD 450,000 | 0.0% |
| 13 | Squarepoint Ops7 funds on PPLI.com | USD 435,000 | 0.0% |
| 14 | Persistent Asset Partners10 funds on PPLI.com | USD 197,000 | 0.1% |
| 15 | The Quarry1 fund on PPLI.com | USD 522 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Fairmount Funds Management | USD 49m | 3.3% |
| 2 | Logos Global Management | USD 34m | 1.5% |
| 3 | Exome Asset Management | USD 2.3m | 1.4% |
| 4 | Persistent Asset Partners | USD 197,000 | 0.1% |
| 5 | RTW Investments | USD 6.7m | 0.1% |
| 6 | Perceptive Advisors | USD 3.7m | 0.1% |
| 7 | Burkehill Global Management | USD 1.3m | 0.0% |
| 8 | Balyasny Asset Management | USD 30m | 0.0% |
| 9 | Moore Capital Management | USD 450,000 | 0.0% |
| 10 | POINT72 Asset Management | USD 5.4m | 0.0% |
Crescent Biopharma, Inc. trades under the symbol CBIO on the Nasdaq. Its CUSIP, the code used on Form 13F, is G2545C104.
15 of the 720 hedge fund managers PPLI.com tracks reported Crescent Biopharma, Inc. shares on Form 13F for 30 June 2026. The largest reported positions were held by Fairmount Funds Management (USD 49m), Logos Global Management (USD 34m), Balyasny Asset Management (USD 30m), Millennium Management (USD 7.3m) and RTW Investments (USD 6.7m).
15 managers in our coverage reported it, and between them they run 210 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Fairmount Funds Management, where the position was 3.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Crescent Biopharma, Inc. or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.